iRhythm Technologies announced the results of a new retrospective analysis, conducted in partnership with Duke Health, that found incorporating ECG data from long-term continuous monitoring can more accurately predict heart failure hospitalization compared to clinical history or risk scores alone. This data was presented at the American Heart Association’s 2023 Scientific Sessions in Philadelphia held November 11-13. The findings of this retrospective analysis of 224,682 patients with 14-day long-term continuous monitoring and clinical data show that a new predictive model for heart failure hospitalization that adds ambulatory ECG features to clinical risk factors resulted in a more accurate discrimination of future heart failure hospitalization compared to clinical risk scores such as CHA2DS2-VASc or atrial fibrillation burden alone. The ambulatory ECG findings with the greatest predictive value were the presence of premature ventricular couplets and presence of Afib. Minimal and maximum heart rate, commonly found in over-the-counter wearable devices, were not predictive or informative.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- New Research Presented at American Heart Association’s 2023 Scientific Sessions Demonstrates Performance of Continuous Monitoring ECG Data for Improved Prediction of Heart Failure Hospitalization
- iRhythm price target lowered to $108 from $140 at Needham
- iRhythm price target lowered to $88 from $116 at Canaccord
- iRhythm price target lowered to $85 from $100 at Citi
- iRhythm price target lowered to $94 from $102 at Baird